stoxline Quote Chart Rank Option Currency Glossary
  
Better Therapeutics, Inc. (BTTX)
0.0105  -0.001 (-4.55%)    07-12 12:52
Open: 0.01
High: 0.0105
Volume: 52,968
  
Pre. Close: 0.011
Low: 0.01
Market Cap: 1(M)
Technical analysis
2024-07-12 1:49:53 PM
Short term     
Mid term     
Targets 6-month :  0.02 1-year :  0.03
Resists First :  0.02 Second :  0.03
Pivot price 0.01
Supports First :  0 Second :  0
MAs MA(5) :  0.01 MA(20) :  0
MA(100) :  0.04 MA(250) :  0.23
MACD MACD :  0 Signal :  -0.1
%K %D K(14,3) :  19.7 D(3) :  21
RSI RSI(14): 49.3
52-week High :  0.88 Low :  0
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BTTX ] has closed below upper band by 49.4%. Bollinger Bands are 85.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 67 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.02 - 0.02 0.02 - 0.02
Low: 0.01 - 0.01 0.01 - 0.01
Close: 0.01 - 0.01 0.01 - 0.01
Company Description

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Headline News

Wed, 20 Mar 2024
BTTX Stock Price and Chart — OTC:BTTX - TradingView

Fri, 15 Mar 2024
Better Therapeutics Overhaul and Nasdaq Delisting - TipRanks

Thu, 14 Mar 2024
Nissan, Honda consider partnering on software, charging infrastructure, Nikkei says By Reuters - Investing.com

Thu, 14 Mar 2024
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq - StockTitan

Thu, 14 Mar 2024
Better Therapeutics Shutters Operations, Terminates Employees, NASDAQ Delisting - HIT Consultant

Thu, 14 Mar 2024
Digital diabetes app maker Better Therapeutics shutters operations, lays off staff - Fierce Biotech

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 55 (M)
Shares Float 24 (M)
Held by Insiders 48.2 (%)
Held by Institutions 0.2 (%)
Shares Short 2,130 (K)
Shares Short P.Month 961 (K)
Stock Financials
EPS -1.11
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.25
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -95.1 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.54
Qtrly Earnings Growth 0 %
Operating Cash Flow -26 (M)
Levered Free Cash Flow -16 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.05
Price to Sales 0
Price to Cash Flow -0.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android